The Latest Cardiac and Vascular News
Gene therapy delivered via CereVasc’s endovascular delivery approach reached key targets in the central nervous system after injection into the cerebellopontine angle resulting in broad biodistribution The eShunt approach has the potential to provide doctors and biopharma partners with a…
BOSTON, Feb. 7, 2024 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that Dr. Pedro Lylyk, Director General of ENERI, will deliver a symposium presentation entitled, “Endovascular Shunting for…
BOSTON, Sept. 26, 2023 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from clinical studies examining the use of its eShunt System to treat elderly patients with normal pressure hydrocephalus and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, was […]
BOSTON, Sept. 18, 2023 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of the study of the eShunt System in patients with Normal Pressure […]
Collaboration Bolsters LianMedical’s Mission to Bring Novel Technologies to the Asian Market and Supports Global Expansion of CereVasc’s Technology BOSTON and SHANGHAI, June 26, 2023 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, and LianMedical, a medical device company focused on accelerating the introduction of breakthrough medical […]
BOSTON, March 28, 2023 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, names Adel Malek, MD PhD as the company’s Chief Medical Officer. This new appointment will allow CereVasc to further accelerate the development and clinical strategy of the eShunt® System, the first […]
BOSTON, Nov. 21, 2022 /PRNewswire/ — Tufts Medical Center neurosurgeons Adel Malek, MD, PhD, Chief of Neurovascular Surgery, and Carl Heilman, MD, Neurosurgeon-in-Chief and Chairman of Neurosurgery, both Co-Founders of CereVasc, Inc. have been honored with the 2022 Innovation Award at the annual meeting of the Society of Vascular and Interventional Neurology (SVIN), for […]
BOSTON, Aug. 29, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced completion of the first eShunt® procedure in the United States. The study, ‘US Pilot Study of the CereVasc eShunt System in Normal Pressure Hydrocephalus (NPH)’, is being conducted under an investigational device […]
US Based Pilot Study to enroll patients who develop communicating hydrocephalus following subarachnoid hemorrhage BOSTON, Aug. 9, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption […]
BOSTON, Feb. 8, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt System in patients […]
